Physician profile
Michael J Page
NPI 1295721223
$4,854.50
in general payments reported to CMS, 2019-2025
27 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $2,801 · 2021: $326 · 2022: $536 · 2023: $387 · 2024: $324 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $1,535.71 | 2019-2020 | |
| Baxter Healthcare | $1,260.00 | 2020 | |
| Medtronic, INC. | $389.08 | 2021-2025 | Signia |
| Stryker Corporation | $388.44 | 2019-2023 | 1688 |
| Abbvie INC. | $260.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $156.43 | 2021-2024 | Dificid, Bridion, Prevymis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.50 | 2021-2023 | Gattex |
| Janssen Biotech, INC. | $93.80 | 2021-2025 | Stelara, Tremfya, Remicade |
| Amgen INC. | $84.47 | 2022-2023 | Avsola, Amjevita |
| Regeneron Healthcare Solutions, INC. | $76.34 | 2023-2025 | Dupixent |
| Intuitive Surgical, INC. | $66.82 | 2023 | Da Vinci Surgical System |
| Acera Surgical, INC. | $55.00 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $35.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $31.78 | 2024 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $27.06 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.59 | 2023 | Cyltezo |
| Qol Medical, LLC | $21.46 | 2024 | Sucraid |
| Celltrion USA INC. | $17.12 | 2024 | Vegzelma |
| Pfizer INC. | $16.57 | 2024 | |
| Ardelyx, INC. | $15.97 | 2023 | Ibsrela |
| Organon LLC | $15.49 | 2024 | |
| Davol INC. | $15.27 | 2024 | Progel Applicator Spray Tips |
| Ferring Pharmaceuticals INC. | $15.10 | 2023 | Rebyota |
| Gilead Sciences, INC. | $14.45 | 2024 | |
| Ironwood Pharmaceuticals, INC | $12.57 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.